This session highlights several important, highly-rated lung cancer abstracts submitted to the STS2021 meeting.

*Unless otherwise noted, speakers have nothing to disclose.

Presentations:

1. Induction Chemotherapy Does Not Improve Survival in cT4N0 (Stage IIIA) Non-Small Cell Lung Cancer Patients with Tumor Size >7 cm - Beatrice Sun

2. A Programmatic Approach Yields Good Results in a Community Lung Cancer Screening Program with a High Histoplasmosis Incidence - Royce Calhoun

3. Pulmonary Open, Robotic and Thoracoscopic Lobectomy (PORTaL) Study: Survival Outcomes Analysis of 6,646 Cases from 21 High-Volume Institutions - Eric Vallieres

Commercial Relationships: Astra-Zeneca: Speaker/Honoraria; Olympus: Consultant/Advisory Board; Oncocyte: Consultant/Advisory Board, Speaker/Honoraria; Spiration: Consultant/Advisory Board

4. Maximum Standardized Uptake Value (SUVmax) on Preoperative PET: Role in Guiding Postoperative Surveillance for Patients with Stage I NSCLC - Alisa Blumenthaler

5. The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes - Chandler Annesi

6. An Artificial Intelligence Algorithm for Predicting Lymph Node Malignancy During Endobronchial Ultrasound - Isabella Churchill

7. Does minimally invasive surgery have a role in extended lobectomy in lung cancer?-An analysis of 3934 cases from NCDB - Jie Zhang

8. A Comprehensive Analysis of Medicare Trends in General Thoracic Surgical Procedures: Sobering Data for Future Conversations - Daniel Rodriguez